The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent, as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.
from Reuters: Company News https://reut.rs/2XNKuJO
via IFTTT
0 comments:
Post a Comment